Although SIRPαFc binds less to CD47 on human erythrocytes than the anti-CD47 antibody, the SIRPαFc-related anemia, thrombocytopenia, and neutropenia still happened in clinically enrolled subjects, thus raising a safety concern (30). This evidence concerns the gene CD47 and neutropenia.